Biopharmaceutical company Elasmogen has secured £8m in a funding round led by BGF and the Scottish National Investment Bank, with additional support from existing investor Scottish Enterprise.
The investment should enable the Aberdeen-based business to continue developing its pipeline of next-generation drugs through pre-clinical trials.
Its soloMER technology is based on molecules naturally found in sharks’ immune systems, which are the equivalent of human antibodies, but smaller and more stable. Elasmogen’s pipeline is focused on applying this to treatments of solid-tumour cancers, systemic inflammatory diseases and inflammatory conditions of the gut.
